Maria Fardis, Iovance CEO (file photo)
May 19, 2021 01:14 PM EDTUpdated 01:37 PM
Cell/Gene Tx

Hours af­ter an­oth­er FDA de­lay, Io­vance CEO re­signs — shares plum­met

Jason Mast

Editor

Here’s a good way to alarm in­vestors: an­nounce that the ap­pli­ca­tion for ap­proval would be de­layed by an­oth­er year and then, less than 20 hours …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times